RxDoctor Payments Data

Tomas Vigo Paredes, MD

General Practice · Chapmanville, WVNPI 1851395834

Payments from drug & device makers

$946in general payments, 2019–2025

Across 57 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • GSK$144
  • Redhill Biopharma Inc.$130
  • Alkermes, Inc.$110
  • Novo Nordisk$61
  • Exact Sciences$57
  • plus $219 from 8 others

What the payments were for

  • Food & beverage$946100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$946 in reported general payments places this provider in the 80th percentile of 437 general practice providers in West Virginia.

See all general practice providers in West Virginia

Medicare billing

Part B allowed, 2024
$53,776
Medicare patients
63
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$49,165
SuboxoneBuprenorphine Hcl/Naloxone Hcl191$45,265
OzempicSemaglutide41$43,373
EliquisApixaban54$37,370
FarxigaDapagliflozin Propanediol48$28,625
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl324$20,232
VascepaIcosapent Ethyl31$18,919
RybelsusSemaglutide21$18,757
TrulicityDulaglutide19$17,533
EntrestoSacubitril/Valsartan18$14,139
XareltoRivaroxaban21$12,299
Breo ElliptaFluticasone/Vilanterol28$10,955
JanuviaSitagliptin Phosphate20$10,685
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,955
SymbicortBudesonide/Formoterol Fumarate29$8,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$144$62,987118 claims
Novo NordiskOzempic, Rybelsus$61$62,13062 claims
Indivior Inc.Suboxone$36$45,265191 claims
PfizerEliquis$20$37,37054 claims
AstraZenecaFarxiga, Symbicort$226$36,96677 claims
Lilly USA, LLCTrulicity$27$17,53319 claims
Redhill Biopharma Inc.Movantik$130$6,42614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 437 general practice providers in West Virginia.

Other general practice in Chapmanville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →